Karampas Grigorios, Karkalemis Konstantinos, Bagiasta Anastasia, Lefaki Maria-Ekaterini, Metallinou Dimitra, Staikou Chryssoula, Iliodromiti Zoi, Sokou Rozeta, Tataropoulou Kassandra, Boutsikou Theodora, Eleftheriades Makarios, Vlahos Nikolaos, Christopoulos Panagiotis, Politou Marianna
Second Department of Obstetrics and Gynaecology, "Aretaieio" University Hospital, Medical School, National and Kapodistrian University of Athens, PC 11528 Athens, Greece.
Laboratory of Heamatology, Blood Transfusion Unit, "Aretaieio" University Hospital, Medical School, National and Kapodistrian University of Athens, PC 11528 Athens, Greece.
Diagnostics (Basel). 2025 Jun 30;15(13):1671. doi: 10.3390/diagnostics15131671.
: Hereditary Fibrinogen Disorders (HFDs) are a group of rare, inherited coagulation disorders with a wide spectrum of clinical presentations, ranging from asymptomatic cases to severe bleeding or thrombotic events. Among these, hereditary hypofibrinogenemia (HH) poses particular challenges in obstetric care due to its unpredictable course and limited evidence-based guidelines. : This case report describes the novel obstetrical management of a 37 years old multiparous woman with severe HH (SHH) guided not only by fibrinogen levels but also by rotational thromboelastometry (ROTEM), a global test of hemostasis using specific parameters such as FIBTEM and NATEM assays. Despite persistent low fibrinogen levels during labor and peripartum (<100 mg/dL), favorable maternal and neonatal outcomes were achieved by relying on ROTEM-based parameters to guide clinical decisions. : Current recommendations for managing pregnancies in women with HFDs are largely based on expert consensus and exclusively use fibrinogen levels. This case supports the use of specific assays (FIBTEM and NATEM) of the ROTEM global test of hemostasis as valuable tools in the obstetric management of women with HH. The use of FIBTEM and NATEM assays could provide individualized perinatal care, avoiding unnecessary therapeutic interventions and aiming for optimal perinatal outcomes.
遗传性纤维蛋白原异常(HFDs)是一组罕见的遗传性凝血障碍,临床表现范围广泛,从无症状病例到严重出血或血栓形成事件。其中,遗传性低纤维蛋白原血症(HH)因其不可预测的病程和基于证据的指南有限,在产科护理中带来了特殊挑战。 本病例报告描述了一名37岁经产妇患有严重HH(SHH)的新型产科管理,不仅以纤维蛋白原水平为指导,还以旋转血栓弹力图(ROTEM)为指导,ROTEM是一种使用FIBTEM和NATEM检测等特定参数的全球止血测试。尽管分娩和围产期纤维蛋白原水平持续较低(<100mg/dL),但通过依靠基于ROTEM的参数指导临床决策,实现了良好的母婴结局。 当前关于HFDs女性妊娠管理的建议主要基于专家共识,且仅使用纤维蛋白原水平。本病例支持将ROTEM全球止血测试的特定检测(FIBTEM和NATEM)用作HH女性产科管理的有价值工具。使用FIBTEM和NATEM检测可为围产期提供个性化护理,避免不必要的治疗干预,并追求最佳围产期结局。